Skip to main content

Table 1 Baseline characteristics of the intent-to-treat population (N = 228)a

From: Correlation of Changes in Patient-Reported Quality of Life With Physician-Rated Global Impression of Change in Patients With Narcolepsy Participating in a Clinical Trial of Sodium Oxybate: A Post Hoc Analysis

Variable Value
Placebo (n = 59) SXB 4.5 g (n = 64) SXB 6 g (n = 58) SXB 9 g (n = 47) Total (N = 228)
Gender, n (%)
 Male 17 (28.8) 21 (32.8) 22 (37.9) 19 (40.4) 79 (34.6)
 Female 42 (71.2) 43 (67.2) 36 (62.1) 28 (59.6) 149 (65.4)
Age, years, mean (SD) 40.8 (15.5) 41.8 (16.7) 39.2 (15.9) 39.9 (12.5) 40.5 (15.3)
Race, n (%)
 White 54 (91.5) 50 (78.1) 49 (84.5) 43 (91.5) 196 (86.0)
 Black 3 (5.1) 11 (17.2) 7 (12.1) 4 (8.5) 25 (11.0)
 Other 2 (3.4) 3 (4.7) 2 (3.4) 0 7 (3.0)
SF-36 score, mean (SD)
 Physical functioning 44.5 (9.9)b 45.9 (10.8) 46.1 (8.0) 43.6 (10.9) 45.1 (9.9)
 Role physical 34.7 (9.4)b 38.0 (11.4) 37.8 (11.1) 35.3 (11.3) 36.6 (10.9)
 Bodily pain 47.8 (10.6)b 50.6 (10.3) 50.9 (10.0) 49.3 (10.1) 49.7 (10.3)
 General health 43.0 (9.1)b 47.5 (10.0) 45.1 (11.4) 45.0 (9.7) 45.2 (10.2)
 Vitality 37.4 (8.9)b 38.9 (10.8) 37.7 (8.9) 36.6 (10.6) 37.8 (9.8)
 Social functioning 34.3 (13.2)b 38.1 (12.8) 37.1 (11.7) 33.6 (13.9) 35.9 (12.9)
 Role emotional 40.8 (13.4)b 45.8 (12.3) 39.9 (13.1) 41.7 (13.9) 42.2 (13.2)
 Mental health 46.2 (9.2)b 45.7 (11.6) 43.5 (10.2) 46.6 (10.5) 45.5 (10.4)
 Physical component summary 42.2 (8.3)b 45.1 (8.5) 46.3 (9.0) 42.7 (8.9) 44.2 (8.8)
 Mental component summary 40.5 (10.6)b 42.7 (12.0) 38.5 (10.2) 40.6 (11.3) 40.6 (11.1)
  1. aIntent-to-treat population was defined as all patients who received at least one dose of double-blind medication and had efficacy data at baseline and Visits 6 (end of titration period) and/or 7 (end of treatment)
  2. b n = 58